T cell immunity and graft-versus-host disease (GVHD)

Yasunori Ichiki, Christopher Bowlus, Shinji Shimoda, Hiromi Ishibashi, John M. Vierling, M. Eric Gershwin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD), induced by the reaction of donor T cells to recipient histoincompatible antigens, is a serious complication of allogeneic bone marrow transplantation (BMT), resulting in considerable morbidity and mortality. In MHC-disparate BMT, donor T cells directly react with major histocompatibility complex (MHC) antigens, while in MHC-matched BMT, T cells react with minor histocompatibility antigens (miHA) presented by shared MHC molecules. Clinically, acute and chronic GVHD can be distinguished on the basis of the time of onset, clinical manifestations and distinct pathobiological mechanisms. Acute GVHD usually occurs within 2 to 6 weeks following allogeneic BMT and primarily affects the skin, liver and the gastrointestinal tract with T cell infiltration of the epithelia of the skin, mucous membranes, bile ducts and gut. In addition, hair follicle cells, airways, bone marrow, and a variety of other tissue systems can be involved. Acute GVHD occurs in up to 50% of allogeneic HLA-matched and 70% of HLA-disparate BMT recipients despite prophylactic immunosuppressive drugs. Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalAutoimmunity Reviews
Volume5
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Graft vs Host Disease
Bone Marrow Transplantation
Immunity
Major Histocompatibility Complex
T-Lymphocytes
Homologous Transplantation
Minor Histocompatibility Antigens
Immune Complex Diseases
Skin
Histocompatibility Antigens
Hair Follicle
Liver Failure
Immunosuppressive Agents
Glomerulonephritis
Bile Ducts
Bone Marrow Cells
Autoantibodies
Gastrointestinal Tract
Mucous Membrane
Epithelium

Keywords

  • Allogeneic bone marrow transplantation
  • Autoantibodies
  • Graft-versus-host disease
  • Major histocompatibility complex

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

T cell immunity and graft-versus-host disease (GVHD). / Ichiki, Yasunori; Bowlus, Christopher; Shimoda, Shinji; Ishibashi, Hiromi; Vierling, John M.; Gershwin, M. Eric.

In: Autoimmunity Reviews, Vol. 5, No. 1, 01.2006, p. 1-9.

Research output: Contribution to journalArticle

Ichiki, Yasunori ; Bowlus, Christopher ; Shimoda, Shinji ; Ishibashi, Hiromi ; Vierling, John M. ; Gershwin, M. Eric. / T cell immunity and graft-versus-host disease (GVHD). In: Autoimmunity Reviews. 2006 ; Vol. 5, No. 1. pp. 1-9.
@article{86d4ea71a2bd452b9c5a52897a0fbf25,
title = "T cell immunity and graft-versus-host disease (GVHD)",
abstract = "Graft-versus-host disease (GVHD), induced by the reaction of donor T cells to recipient histoincompatible antigens, is a serious complication of allogeneic bone marrow transplantation (BMT), resulting in considerable morbidity and mortality. In MHC-disparate BMT, donor T cells directly react with major histocompatibility complex (MHC) antigens, while in MHC-matched BMT, T cells react with minor histocompatibility antigens (miHA) presented by shared MHC molecules. Clinically, acute and chronic GVHD can be distinguished on the basis of the time of onset, clinical manifestations and distinct pathobiological mechanisms. Acute GVHD usually occurs within 2 to 6 weeks following allogeneic BMT and primarily affects the skin, liver and the gastrointestinal tract with T cell infiltration of the epithelia of the skin, mucous membranes, bile ducts and gut. In addition, hair follicle cells, airways, bone marrow, and a variety of other tissue systems can be involved. Acute GVHD occurs in up to 50{\%} of allogeneic HLA-matched and 70{\%} of HLA-disparate BMT recipients despite prophylactic immunosuppressive drugs. Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation.",
keywords = "Allogeneic bone marrow transplantation, Autoantibodies, Graft-versus-host disease, Major histocompatibility complex",
author = "Yasunori Ichiki and Christopher Bowlus and Shinji Shimoda and Hiromi Ishibashi and Vierling, {John M.} and Gershwin, {M. Eric}",
year = "2006",
month = "1",
doi = "10.1016/j.autrev.2005.02.006",
language = "English (US)",
volume = "5",
pages = "1--9",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - T cell immunity and graft-versus-host disease (GVHD)

AU - Ichiki, Yasunori

AU - Bowlus, Christopher

AU - Shimoda, Shinji

AU - Ishibashi, Hiromi

AU - Vierling, John M.

AU - Gershwin, M. Eric

PY - 2006/1

Y1 - 2006/1

N2 - Graft-versus-host disease (GVHD), induced by the reaction of donor T cells to recipient histoincompatible antigens, is a serious complication of allogeneic bone marrow transplantation (BMT), resulting in considerable morbidity and mortality. In MHC-disparate BMT, donor T cells directly react with major histocompatibility complex (MHC) antigens, while in MHC-matched BMT, T cells react with minor histocompatibility antigens (miHA) presented by shared MHC molecules. Clinically, acute and chronic GVHD can be distinguished on the basis of the time of onset, clinical manifestations and distinct pathobiological mechanisms. Acute GVHD usually occurs within 2 to 6 weeks following allogeneic BMT and primarily affects the skin, liver and the gastrointestinal tract with T cell infiltration of the epithelia of the skin, mucous membranes, bile ducts and gut. In addition, hair follicle cells, airways, bone marrow, and a variety of other tissue systems can be involved. Acute GVHD occurs in up to 50% of allogeneic HLA-matched and 70% of HLA-disparate BMT recipients despite prophylactic immunosuppressive drugs. Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation.

AB - Graft-versus-host disease (GVHD), induced by the reaction of donor T cells to recipient histoincompatible antigens, is a serious complication of allogeneic bone marrow transplantation (BMT), resulting in considerable morbidity and mortality. In MHC-disparate BMT, donor T cells directly react with major histocompatibility complex (MHC) antigens, while in MHC-matched BMT, T cells react with minor histocompatibility antigens (miHA) presented by shared MHC molecules. Clinically, acute and chronic GVHD can be distinguished on the basis of the time of onset, clinical manifestations and distinct pathobiological mechanisms. Acute GVHD usually occurs within 2 to 6 weeks following allogeneic BMT and primarily affects the skin, liver and the gastrointestinal tract with T cell infiltration of the epithelia of the skin, mucous membranes, bile ducts and gut. In addition, hair follicle cells, airways, bone marrow, and a variety of other tissue systems can be involved. Acute GVHD occurs in up to 50% of allogeneic HLA-matched and 70% of HLA-disparate BMT recipients despite prophylactic immunosuppressive drugs. Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation.

KW - Allogeneic bone marrow transplantation

KW - Autoantibodies

KW - Graft-versus-host disease

KW - Major histocompatibility complex

UR - http://www.scopus.com/inward/record.url?scp=28744453704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28744453704&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2005.02.006

DO - 10.1016/j.autrev.2005.02.006

M3 - Article

C2 - 16338205

AN - SCOPUS:28744453704

VL - 5

SP - 1

EP - 9

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 1

ER -